Siga este enlace para ver otros tipos de publicaciones sobre el tema: Pharma marketing.
Artículos de revistas sobre el tema "Pharma marketing"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Pharma marketing".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
1
Jeffreys, Diarmund. "4th Annual Pharmaceutical Marketing Conference ‘Marketing ROI for Pharma’". Journal of Medical Marketing 5, n.º 2 (1 de abril de 2005): 182. http://dx.doi.org/10.1057/palgrave.jmm.5040226.
Texto completo
2
Röleke, Dietmar. "Aus dem Labor ins Pharma-Marketing". Nachrichten aus der Chemie 53, n.º 9 (septiembre de 2005): 976–77. http://dx.doi.org/10.1002/nadc.20050530954.
Texto completo
3
Behnke, Nils. "Marketing Strategy: How biotechnology and speciality pharma companies can beat big pharma in marketing cancer drugs". Journal of Medical Marketing 5, n.º 1 (1 de enero de 2005): 10–14. http://dx.doi.org/10.1057/palgrave.jmm.5040195.
Texto completo
4
Mattson, William. "Global Pharma 20/20". Journal of Pharmaceutical Marketing & Management 10, n.º 2/3 (22 de marzo de 1996): 3–18. http://dx.doi.org/10.1300/j058v10n02_02.
Texto completo
5
Jain, Abhinandan K., G. Raghuram y Pramod K. Agrawal. "Kalyan Pharma Ltd." Vikalpa: The Journal for Decision Makers 18, n.º 3 (julio de 1993): 37–48. http://dx.doi.org/10.1177/0256090919930305.
Texto completoResumen
The case presented in this issue focuses on the interaction between the logistics and marketing aspects of KPL�a frontrunner in the pharmaceutical industry. The key strategic question is what distribution system to have to ensure good customer service as well as improved profitability. Readers are requested to send their responses on the case to Vikalpa office.
6
Bajaj, Hrithik. "E-Pharma System". International Journal for Research in Applied Science and Engineering Technology 9, n.º VII (31 de julio de 2021): 3724–27. http://dx.doi.org/10.22214/ijraset.2021.37172.
Texto completoResumen
The primary goal of this program's development is to deliver all medical-related solutions in a single web application. E-Pharma is a platform that allows patients and doctors to communicate directly with one another. Direct doctor-patient relationships, consumer familiarity with online purchases, the simplicity of mail-order trading, and distance marketing can all help patients self-diagnose. The patient can speak with the doctor and ask questions.
7
Walther, Hans-Peter y Peter Wahle. "Strategisches Pharma-Marketing. Chance in turbulenter Umwelt". Marketing ZFP 12, n.º 1 (1990): 31–40. http://dx.doi.org/10.15358/0344-1369-1990-1-31.
Texto completo
8
&NA;. "Pharma marketing techniques might improve drug safety". Reactions Weekly &NA;, n.º 1232 (diciembre de 2008): 1. http://dx.doi.org/10.2165/00128415-200812320-00001.
Texto completo
9
Bhardwaj, Shubham, Rajeshwar Verma, Romil Sharma y Rahul Solakhia. "PHARMACOVIGILANCE: DYNAMICS IN INDIAN PHARMA INDUSTRY". Indian Journal of Pharmaceutical and Biological Research 6, n.º 01 (31 de marzo de 2018): 30–33. http://dx.doi.org/10.30750/ijpbr.6.1.5.
Texto completoResumen
Pharmacovigilance refers to the process of identifying, detecting, and responding to drug safety issue and has witnessed dynamic advancements in pharmaceutical industries throughout the world. The main objective of pharmacovigilance is to extend the safety monitoring and to detect any ADRs that previously got unrecognized in evolution during clinical trial. ADRs monitoring is required for each medicine throughout its lifecycle which includes early stage of drug design, clinical trials, and post marketing surveillance. The emerging trend in pharmacovigilance is to link the pre marketing data with the data collected during post marketing phase that include safety information. India is a vast country with population of over 1.32 Billion with different social economics status, different patterns of disease prevalence it becomes more important to have a standardized and robust pharmacovigilance. Pharmacists, as doctor remark that their involvement may increase the reporting rate and have a greater role to play in the area of pharmacovigilance
10
Obara, Naoshi, Haruhiko Ninomiya, Shigeru Chiba, Kensuke Usuki, Kaichi Nishiwaki, Itaru Matsumura, Tsutomu Shichishima et al. "Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan". Blood 124, n.º 21 (6 de diciembre de 2014): 4870. http://dx.doi.org/10.1182/blood.v124.21.4870.4870.
Texto completoResumen
Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease characterized by chronic complement-mediated hemolysis, leading to life-threatening events, such as thromboembolism (TE) and chronic kidney disease (CKD), and devastated quality of life (QOL). The terminal complement inhibitor eculizumab (ECU) was approved in Japan in 2010 under the indication to suppress hemolysis in PNH. We comprehensively report as post marketing surveillance (PMS) on the efficacy and safety of ECU administered from June 2010 to March 2013 in Japanese patients with PNH. In spite of complete blocking hemolysis, the degree of improvement of anemia by ECU treatment varies patient by patient. Analyzing the data of PMS, we investigated if patient characteristics, such as LDH, bone marrow function and renal function, can affect anemia in PNH patients treated with ECU. Methods: The PMS data of 242 patients were used for demographics and safety assessment. Of 242, 144 patients with ECU treatment at least for 1 year were analyzed for efficacy evaluation. We used platelet (PLT) count as a marker of bone marrow function and divided it into three groups, <88 (Low), 88-155 (Mid) and ≧155 x109/L (High). We also utilized CKD stage calculated by estimated GFR (eGFR) which is widely accepted as a renal function classification, eGFR <60 (CKD stage 3-5), 60-90 (CKD stage 2) and ≧90 mL/min/1.73m2 (CKD stage 0/1), according to Japanese CKD guideline. Results: In Japan LDH>1000 IU/L is commonly considered as ECU applicable severe PNH patients, but this was not correlated with other markers related to PNH severity. 41.2% of patients who started ECU had eGFR <60 mL/min/1.73m2, CKD stage 3-5. The prevalence of CKD stage 3-5 in PNH population was much higher than that of the normal Japanese population, especially in PNH patients over 65 years old. ECU treatment dramatically and quickly reduced the serum level of LDH, and 18-month (median)-teatment with ECU increased hemoglobin level by 1.9 g/dL, reduced annual transfusion units by half, made 55.3% of transfusion-dependent patients transfusion-independent, improved one CKD stage in 29% of the patients with CKD stage 3-5 and made 14% returned to CKD stage 2. Side effects of all grades associated with ECU were reported in 36.8% of patients and severe ones were observed in 8.3%, which include 10 infectious events in 8 patients. 18-month-treatment with ECU increased hemoglobin (Hb) level by 1.2 g/dL in the Low-PLT, 1.5 g/dL (p<0.001) in the Mid-PLT and 2.9 g/dL (p<0.001) in the High-PLT group and reduced annual RBC transfusion (TF) unit 21.6→11.3 (p=0.002), 11.0→7.0 and 10.0→1.1 (p<0.001), respectively. ECU augmented Hb level by 2.4 g/dL (p<0.001) in CKD stage 0/1, 2.3 g/dL (p<0.001) in CKD stage 2 and 1.1 g/dL (p=0.022) in CKD stage 3-5 and decreased annual TF units 13.4→2.9 (p<0.001), 11.5→3.3 (p=0001) and 16.5→10.4 (p=0.036), respectively. Conclusion: ECU treatment for 18 months reduced hemolysis and improved anemia, renal function and QOL. It is concluded that ECU is safe and well tolerated. Anemia in PNH would be caused not only by hemolysis but also modified by bone marrow as well as renal function. Disclosures Obara: Alexion Pharma: Research Funding. Ninomiya:Alexion Pharma: Honoraria, Research Funding. Chiba:Alexion Pharma: Research Funding. Usuki:Alexion Pharma: Speakers Bureau. Shichishima:Alexion Pharma: Honoraria, Research Funding. Nishimura:Alexion Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Ohyashiki:Alexion Pharma: Honoraria, Research Funding. Nakao:Alexion Pharma: Honoraria, Research Funding. Ando:Alexion Pharma: Research Funding. Kawaguchi:Alexion Pharma: Honoraria, Research Funding. Nakakuma:Alexion Pharma: Honoraria. Hamada:Alexion Pharma: Employment. Shimono:Alexion Pharma: Employment. Kinoshita:Alexion Pharma: Honoraria. Ozawa:Alexion Pharma: Honoraria. Omine:Alexion Pharma: Honoraria. Kanakura:Alexion Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.
11
Khan, Md Mahfuzur Rahman y Kona Basak. "Shifts in Pharma-Marketing Trends in Post COVID-19 Era". International Journal of Multidisciplinary: Applied Business and Education Research 2, n.º 2 (12 de febrero de 2021): 108–14. http://dx.doi.org/10.11594/ijmaber.02.02.04.
Texto completoResumen
The study reveals that there will be shift in pharma-marketing trends in post COVID-19 era. The crisis of COVID-19, which responded in lockdowns and social distancing, highlighted in some key elements in the digital transformation of healthcare. Therewith the marketing techniques changes totally in the field of pharmaceuticals. As, this is an explorative research so qualitative data has been used for conducting the research. A total number of 100 practitioners’ such as doctors, physicians, psychiatrist, medical representatives and pharmacist were selected for the interview via judgment sampling technique. The time-frame of this study is in between March 2020 to December 2020. The deductive approach is used in reaching the conclusive decision on the shift in pharma-marketing in post COVID-19 era. Review of literature asserted about negative impacts of disruptions throughout the pandemics in past, though every pandemics created new opportunities. So to survive and to sustain pharmaceutical field and conjugate industries should now focus more on new marketing tactics, to counter COVID-19 side effects. Findings of the study educe that pharmaceutical industry could encounter the global pandemic by the shifts in pharma marketing strategies including advanced marketing, digital marketing, e-detailing customer relationship management, e-sampling, innovative work behavior, telemedicine revolution in order to promoting product value and expediting prescriptions to the target consumer. So, coping up with the new normal and digitalizing the possible aspects of health care and medicines including techniques of pharma-marketing can be advantageous for both individuals and organizations.
12
Street, Alice. "Food as pharma: marketing nutraceuticals to India’s rural poor". Critical Public Health 25, n.º 3 (14 de octubre de 2014): 361–72. http://dx.doi.org/10.1080/09581596.2014.966652.
Texto completo
13
Winnat, Christoph. "Pharma-Marketing: Neuer Kodex nur für FSA-Mitglieder verpflichtend". DNP - Der Neurologe und Psychiater 15, n.º 9 (28 de agosto de 2014): 29. http://dx.doi.org/10.1007/s15202-014-0868-9.
Texto completo
14
Chhabra, Gurpreet Kaur. "Factors Influencing the Prescription Behaviour of Doctors-An Insight for the Pharmaceutical CRM Strategy Formulation". IRA-International Journal of Management & Social Sciences (ISSN 2455-2267) 15, n.º 4 (27 de agosto de 2019): 131. http://dx.doi.org/10.21013/jmss.v15.n4.p6.
Texto completoResumen
<p>Marketing has always been a major thrust area for the Pharmaceutical industry. Pharma firms usually bear a huge expenditure on marketing, especially sales efforts. Marketing in the Pharmaceutical industry is mainly done through personal selling techniques of promotion through MRs.Marketing of pharmaceutical products to doctors takes place through relationship marketing. Company representatives called medical reps meet the doctors in their specific geographic territory and promote their products to them. The doctors, in turn, prescribe the products to the patients who buy them from the chemist shop. Factors influencing doctor’s prescription behaviour can be classified into three categories: Socio-cultural factors, Personal-Psychological factors, Pharma Marketing factors. Now a day’s companies give a major thrust to the CRM aspect of their marketing strategies. Customer relationship management (CRM) is the strategic process of shaping the interaction between a company and its customers with the goal of maximizing current and lifetime value of customers for the company as well as maximizing, satisfaction for customers.CRM helps Pharma companies to generate revenue from shelf life by reaching more new prescribers (doctors) and patients (end customer) thereby keeping them loyal by increasing their well- being.</p>
15
Bhangale, Vijay. "Pharma marketing in India: Opportunities, challenges and the way forward". Journal of Medical Marketing 8, n.º 3 (junio de 2008): 205–10. http://dx.doi.org/10.1057/palgrave.jmm.5050121.
Texto completo
16
Molé, Ronald B. "Big ‘bad’ pharma". Journal of Medical Marketing 5, n.º 3 (1 de julio de 2005): 261–63. http://dx.doi.org/10.1057/palgrave.jmm.5040238.
Texto completo
17
Fujii, T., T. Atsumi, N. Okamoto, N. Takahashi, N. Tamura, A. Nakajima, A. Nakajima et al. "AB0249 SAFETY OF BARICITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA): THE 2020 INTERIM REPORT FROM ALL-CASE POST MARKETING SURVEILLANCE IN CLINICAL PRACTICE". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de mayo de 2021): 1150.1–1150. http://dx.doi.org/10.1136/annrheumdis-2021-eular.433.
Texto completoResumen
Background:An all-case post marketing surveillance (PMS) of baricitinib (Bari), that started in Sep 2017, collects safety and effectiveness for the first 24 wks of treatment and continues to collect serious adverse events (SAEs) for 3 yrs.Objectives:To evaluate Bari safety in RA patients (pt) in clinical practice.Methods:We report pt baseline demographics and adverse events (AEs) up to 24 wks for pts whose case report files for 24-wk data were completed as of Jun 2020.Results:Data from 3445 pts were analyzed (females=80%, mean age=64yr, mean RA duration 12yr). Bari dose regimen was as follows: 4mg, 60%, 2mg, 27%, 4mg→2mg, 5%, 2mg→4mg, 5%, and others, 2%. Concomitant use of MTX and glucocorticoid was 65% and 48%, respectively. 74% continued treatment for 24 wks. AE and SAE were recognized in 887 (26%) and 122 pts (4%), respectively. 6 pts died of pneumonia, aspiration pneumonia, bacterial pneumonia, cerebral infarction/ILD/aspiration pneumonia, adenocarcinoma, and colorectal cancer. Major AEs were as follows: herpes zoster=3%, liver dysfunction=3%, serious infection=1%, anemia=1%, hyperlipidemia=1%, malignancy=0.3%, interstitial pneumonia=0.2%, MACE=0.1%, and VTE=0.1%.Conclusion:Data do not show new safety concerns and encourage guideline-compliant use of Bari.Disclosure of Interests:Takao Fujii Speakers bureau: Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; Ono Pharmaceutical Co. Ltd., Consultant of: Asahikasei Pharma Corp, Grant/research support from: Asahikasei Pharma Corp; AbbVie Japan GK; Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Ono Pharmaceutical Co., Ltd., Tatsuya Atsumi Speakers bureau: AbbVie Japan GK; Astellas Pharma Inc.; Bristol-Myers Squibb Co. Ltd; Chugai Pharmaceutical Co. Ltd.; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., Consultant of: AbbVie Japan GK; AstraZeneca plc.; Boehringer Ingelheim Co. Ltd.; Medical & Biological Laboratories Co. Ltd.; Novartis Pharma K.K.; Ono Pharmaceutical Co. Ltd.; Pfizer Japan Inc., Grant/research support from: Astellas Pharma Inc., Alexion Inc.; Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Ltd.Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd., Nami Okamoto Speakers bureau: AbbVie Japan GK; Asahikasei Pharma Co.; AYUMI Pharmaceutical Co.Eisai Co. Ltd; Bristol-Myers Squibb Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Pfizer Japan Inc.Sanofi K.K.; Chugai Pharmaceutical Co. Ltd.; Novartis Pharma Co.; Teijin Pharma Ltd.; Torii Pharmaceutical Co., Ltd., Nobunori Takahashi Speakers bureau: AbbVie Japan GK; Eisai Co. Ltd.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; UCB Japan Co. Ltd.; Astellas Pharma Inc.; Bristol Myers Squibb Co. Ltd., Grant/research support from: Bristol Myers Squibb Co. Ltd., Naoto Tamura Speakers bureau: AbbVie Japan GK; Bristol Myers Squibb Co. Ltd.; Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Glaxo Smith Kline K.K.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co., Atsuo Nakajima: None declared, Ayako Nakajima Speakers bureau: AbbVie Japan GK; Actelion Pharmaceuticals Japan Ltd., Asahi Kasei Pharma Co., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd.,Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Glaxo Smith Kline K.K., Hisamitsu Pharmaceutical Co. Inc., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Teijin Pharma Ltd., Grant/research support from: Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Hiroaki Matsuno Speakers bureau: Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Consultant of: Mochida Pharmaceutical Co., Ltd., Grant/research support from: Astellas Pharma Inc., Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K, Naoto Tsujimoto Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Atsushi Nishikawa Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Taeko Ishii Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Tsutomu Takeuchi Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan K.K.; Gilead Sciences, Inc. Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co.; Pfizer Japan Inc.; Sanofi K.K.; UCB Japan Co., Ltd., Consultant of: AbbVie Japan GK, Astellas Pharma, Inc.; Chugai Pharmaceutical Co, Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Gilead Sciences, Inc.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Corp., Pfizer Japan Inc., Grant/research support from: AbbVie Japan GK, Asahikasei Pharma Corp., Chugai Pharmaceutical Co, Ltd., DNA Chip Research Inc.; Eisai Co., Ltd., Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp., UCB Japan Co., Ltd., Masataka Kuwana Speakers bureau: AbbVie Japan GK, Astellas Pharma Inc., Asahi Kasei Pharma Co., Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Medical &Biological Laboratories Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Pfizer Japan Inc., Consultant of: Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Corbus Pharmaceuticals Holdings, Inc.; Medical &Biological Laboratories Co., Ltd.; Mochida Pharmaceutical Co., Ltd., Grant/research support from: Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Medical &Biological Laboratories Co., Ltd; Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., Ltd., Michiaki Takagi Speakers bureau: Yes, but sponsored lectures without COI in the academic meetings, only.
18
Harrop, Chris, John Read, Jim Geekie y Julia Renton. "An Independent Audit of Pharma Influence in Public Mental Health Trusts in England". Ethical Human Psychology and Psychiatry 20, n.º 3 (1 de diciembre de 2018): 156–68. http://dx.doi.org/10.1891/1559-4343.20.3.156.
Texto completoResumen
Without data, many people may think pharmaceutical companies' influence over mental health services is negligible. We audited the marketing activities of, and payments to, drug companies in relation to public mental health services in England. Forty-three of 53 Trusts responded to Freedom-of-Information-Act requests. Trusts' policies varied in covering seven activities: from 86% (gifts) to 37% (leaflets). In practice, industry-sponsored training events (51%) and direct talks (40%) were common (averaging 36 events or talks per Trust annually). Only 22% of Trusts produced legally required Conflicts-of-Interests registers; and 14% had none. All 22 Trusts that reported which company received the largest share of their drug expenditure named the same company. On average, Trusts spent 44% of their drugs budget on long-acting injectable antipsychotics (13% to 77%) and 32% on brand name drugs (5%–74%). Five Trusts ban the Pharma marketing activities investigated. Independent post-qualification medical education, and marketing-bans, are needed to avoid over-medicalized practice.
19
&NA;. "Ciclesonide [Alvesco; Altana Pharma] has been approved for marketing in the UK",. Inpharma Weekly &NA;, n.º 1435 (mayo de 2004): 21. http://dx.doi.org/10.2165/00128413-200414350-00055.
Texto completo
20
Nath Sanyal, Shamindra, Saroj Kumar Datta y Asok Kumar Banerjee. "Conceptualisation of branding: strategy based on the Indian pharma sector". International Journal of Pharmaceutical and Healthcare Marketing 7, n.º 2 (21 de junio de 2013): 175–98. http://dx.doi.org/10.1108/ijphm-04-2013-0013.
Texto completo
21
Habernickel, Valentin. "The Pharma Market as Reflected by Patents - Information for Marketing and Scientific Work". Arzneimittelforschung 50, n.º 04 (27 de diciembre de 2011): 409–12. http://dx.doi.org/10.1055/s-0031-1300222.
Texto completo
22
Habernickel, Valentin. "The Pharma Market as Reflected by Patents Information for Marketing and Scientific Work". Arzneimittelforschung 49, n.º 01 (28 de diciembre de 2011): 60–63. http://dx.doi.org/10.1055/s-0031-1300360.
Texto completo
23
Amsbaugh, Pamela y Dennis A. Pitta. "New product introduction at TyRx Pharma, Inc." Journal of Product & Brand Management 15, n.º 7 (1 de diciembre de 2006): 468–72. http://dx.doi.org/10.1108/10610420610712865.
Texto completoResumen
Purpose – To describe a practice that has implications for new product introduction within and outside the medical products industry. Design/methodology/approach – The case describes a systems approach to new product introduction that includes a number of non‐marketing factors. The organization's original name has been retained. One of the authors is an executive with the company and used both internal and publicly available data to write the case study. Findings – The case provides information and a solid action approach to new product launch. The subject company designed a comprehensive launch strategy that involved new product modification as well as selection of appropriate price and distribution strategies. The results offer direct implications for new product development teams in the drug and medical implements industries. Research limitations/implications – As in all case studies, the specific conditions found in one organization may not be found more generally in others. Readers are cautioned that the conclusions drawn in the case may have limited applicability. Practical implications – The case depicts a professional implementation of a new product launch. Other organizations may find the technique of value in their own efforts. Originality/value – The case is a unique implementation of a new product launch strategy that has a comprehensive foundation. It offers lessons that may be applied to other companies faced with similarly competitive, regulatory and technological environments.
24
RINDERHOFER. "Computational Fluid Dynamics, Sophisticated Marketing Tool or Reliable Method for Pharma- and Biotech Processes". Scientia Pharmaceutica 78, n.º 3 (2010): 565. http://dx.doi.org/10.3797/scipharm.cespt.8.lpes04.
Texto completo
25
Kilgallon, William. "The Henley Pharma Forum — Henley Management College". Journal of Medical Marketing 5, n.º 4 (1 de noviembre de 2005): 388–90. http://dx.doi.org/10.1057/palgrave.jmm.5040259.
Texto completo
26
&NA;. "BioAlliance Pharma has been granted Marketing Authorisation for miconazole [Loramyc] in the UK and Denmark." Inpharma Weekly &NA;, n.º 1621 (enero de 2008): 22. http://dx.doi.org/10.2165/00128413-200816210-00057.
Texto completo
27
Costa, Aline De Carvalho, Késia Marques Soares, Luis Felipe De Oliveira Cavalcante y Fabiana Da Silva Leite. "Estratégias de marketing para o posicionamento competitivo: estudo de caso da farmácia de manipulação Magistral Pharma". Revista InterScientia 6, n.º 2 (7 de diciembre de 2018): 51–66. http://dx.doi.org/10.26843/interscientia.v6i2.731.
Texto completoResumen
Para que as empresas se mantenham competitivas no mercado necessitam ter um posicionamento estratégico que oriente o crescimento da organização, independente do cenário econômico vigente. Uma das formas de buscar o posicionamento competitivo é através da elaboração de um plano estratégico de Marketing, que permita à organização analisar o seu ambiente interno e externo, redefinir os seus objetivos assim como a sua estrutura interna, por meio da reformulação da missão e visão, reconhecendo os seus pontos fortes e fracos, fazendo uso do Benchmarking para definir as estratégias a serem implementadas em relação ao mercado e à concorrência. O presente trabalho utilizou a metodologia de estudo de caso com o objetivo de analisar as melhores estratégias de Marketing a serem utilizadas na Magistral Pharma Farmácia de Manipulação LTDA-ME, localizada na cidade de Rio Bonito-RJ, propondo a aplicação da teoria na vivência de uma empresa, tendo como resultado o início do seu processo de reposicionamento no mercado.
28
Takeshita, Akihiro, Takaaki Ono, Yumi Kojima, Taiichi Kyo, Norio Asou, Hitoshi Suzushima, Fumiharu Yagasaki et al. "Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on Relapsed/Refractory Acute Promyelocytic Leukemia (APL)". Blood 118, n.º 21 (18 de noviembre de 2011): 1532. http://dx.doi.org/10.1182/blood.v118.21.1532.1532.
Texto completoResumen
Abstract Abstract 1532 The current standard initial treatment for APL is all-trans retinoic acid (ATRA) and anthracycline with or without citarabine, followed by ATRA maintenance. Although the treatment has greatly improved clinical outcomes of APL, a considerable proportion of patients still undergo disease relapse, requiring salvage therapy with such as arsenic trioxide (ATO). GO, an anti-CD33 monoclonal antibody conjugated with calicheamicin, is also highly effective on APL. Highly homogeneous expression of CD33, potential efficacy of calicheamicin and lower expression of P-glycoprotein on APL cells explain the high potency of GO on APL. We report here on the efficacy of GO monotherapy against relapsed/refractory APL in a post-marketing surveillance study of GO in Japan. All patients who were treated with GO alone were obligatorily registered into a post-marketing surveillance study run by Wyeth Japan, Co. Ltd. under the guidance of the Pharmaceutical and Medical Devices Agency. We obtained permission to access patients' data from each institution and Pfizer Japan, Co. Ltd. The survey items included adverse events, treatment outcome, overall survival (OS) and relapse-free survival (RFS). Clinical and biological characteristics were analyzed in APL and compared by chi-square test or Fisher's exact test for categorical data, and Wilcoxon rank-sum test for continuous data. OS and RFS were estimated by the Kaplan-Meier method in APL, and then compared to those from the simultaneous post-marketing study in acute myeloid leukemia (AML) by the log-rank test. Between 2005 and 2008, 27 relapsed/refractory APL patients were enrolled in this surveillance. Of these, two patients were excluded from analysis because of insufficient data, while 726 AML patients were enrolled and 503 were evaluable. Twelve (48%) and 2 (9%) APL patients who were treated with GO alone achieved CR and CRp, respectively, while 42 (8%) and 41 (8%) of AML achieved CR and CRp, respectively. Remission duration of first CR and number of relapses influenced CR rates, but previous usage of ATO and age did not in APL. OS and RFS at 2 years were 63% and 71% in APL, and 14% and 20% in AML, respectively. These were shown in figures. OS and RFS in APL were better than those in AML (P<0.0001 and P=0.0074, respectively). Treatment related adverse events of GO (grade 3 or 4) in APL patients were infection (24%), bleeding (8%), lung damage (4%) and reversible veno-occlusive disease (4%); these were similar in AML patients. Although other previous clinical studies failed to confirm clinical benefit of GO on AML, single use of GO is highly effective and relatively safe in relapsed/refractory APL. The efficacy was also observed in elderly patients and in relapsed ones after ATO therapy. Further studies are warranted, in which GO is included in addition to ATRA and ATO in the treatment of high-risk APL. Disclosures: Takeshita: Novartis Pharma: Research Funding; Takeda Pharma: Research Funding. Naoe:Kyowa-Hakko Kirin.: Research Funding; Dainipponn-Sumitomo Pharma.: Research Funding; Chugai Pharma.: Research Funding; Novartis Pharma.: Honoraria, Speakers Bureau; Zenyaku-Kogyo: Research Funding; Otsuka Pharma.: Research Funding.
29
Alkhateeb, Fadi y Ephantus Gaitho. "Vault Career Guide to Pharmaceutical Sales and Marketing: Get the Inside Scoop on Pharma Sales and Marketing Careers20111Carole S. Moussalli. Vault Career Guide to Pharmaceutical Sales and Marketing: Get the Inside Scoop on Pharma Sales and Marketing Careers. 2006. 196 pp., ISBN: 978‐1581313864 Vault Inc. New York, NY". International Journal of Pharmaceutical and Healthcare Marketing 5, n.º 3 (6 de septiembre de 2011): 234–36. http://dx.doi.org/10.1108/17506121111172239.
Texto completo
30
Van den Bogaert, Sarah, Jana Declercq, Thierry Christiaens, Geert Jacobs y Piet Bracke. "In the land of pharma: A qualitative analysis of the reputational discourse of the pharmaceutical industry". Public Relations Inquiry 7, n.º 2 (mayo de 2018): 127–47. http://dx.doi.org/10.1177/2046147x18774588.
Texto completoResumen
The pharmaceutical industry has been battling a negative reputation and has been confronted with accusations such as putting profits before patients and manipulating clinical trial results. In this study, we focus on how pharmaceutical companies address what we define as the Bad Pharma discourse. Drawing on interviews, press releases, corporate documentation and ethnographic fieldwork, we analyse the main themes that are used by the Belgian pharmaceutical industry to construct its reputational discourse, and we focus on how this discourse is shaped by the Bad Pharma discourse. Our results illustrate that on the one hand, the industry contests the Bad Pharma discourse by generating an alternative discourse. On the other hand, they also partly embrace and reframe this Bad Pharma discourse. This way, current societal debates are entextualised in the reputational discourses of the pharmaceutical industry.
31
Viswanath Bandi y Rao O R S. "Role of Physician’s Personality on their Drug Prescription Behavior". International Journal of Research in Pharmaceutical Sciences 11, n.º 4 (19 de diciembre de 2020): 6954–61. http://dx.doi.org/10.26452/ijrps.v11i4.3700.
Texto completoResumen
Physicians Prescription behavior is the results of 4P's namely Product, Physicians, Promotion, and Patient's expectation. In today's world of evidence-based medicine with ever-growing demand in patient expectations, physician- Patient-centric managing a pathological condition is gaining acceptance from the normal disease management approach. Like all citizenry is Unique; similarly, physicians also possess a singular personality that responds differently even to an equivalent stimulus. Aiming for better patient care and Patient expectations, research work across the world has been administered for identifying the perfect physician personality traits right from selection of specialty, knowledge dissemination during the study period, and managing patients during the Practice sessions. However, there's little, or no research conducted thus far, in understanding the "Physician's personality" make-up focussing on their motives, values, preferences in their professional practice. Understanding "physician's personality" traits will lay a robust foundation for developing effective medico-marketing initiatives from the pharmaceutical industry with the assistance of smart and customized marketing initiatives resulting in a healthy environment for physician-Pharma association towards adopting better therapeutic interventions for patient benefit. This review is an effort to specialize in the research work done thus far in understanding the impact of "physician's personality" aimed toward improving patient care. Further research in understanding "Physician's personality" and its role in physicians prescribing decisions will help the Pharma industry towards developing much needed medico-marketing initiatives with optimal utilization of resources towards disseminating the latest therapeutic interventions to the physicians for better patient care which is the stepping stone for Physician-patient centric management.
32
Padela, Shoaib M. Farooq, Jawaid Ahmed Qureshi y Salman Bashir. "Applying marketing conventions on pharmaceutical generics: an analysis of Starpram brand from Maple Pharmaceuticals". Emerald Emerging Markets Case Studies 9, n.º 4 (13 de diciembre de 2019): 1–22. http://dx.doi.org/10.1108/eemcs-11-2019-0294.
Texto completoResumen
Learning outcomes Learning outcomes (objectives and outcomes) are as follows: to understand the brand positioning, brand building and category extension decisions of a pharmaceutical brand (operative in one of the most competitive and regulated industries in a developing country); to analyze the outcomes of decisions pertaining strategic sales, branding, marketing and strategic restructuring to overcome the challenges of growth; and to design strategic solutions for developing brand equity. Case overview/synopsis This case explores the strategy of launching and establishing a pharmaceutical brand in an industry that tends to be a highly technical and the most regulated industry. It depicts market research data, industry analysis, stiff competition and regulatory affairs, and elaborates various strategic decisions taken by the company. The primary data for the case is accumulated through in-depth interviews from six industry experts on pharma marketing who were well acquainted with Maple Pharma and secondary data is gleaned from substantive literature. Maple Pharmaceuticals launched Starpram, a high-growth, high-potential generic antidepressant brand (in the central nervous system category) containing Escitalopram molecule/chemical. It had expertise cum competitive advantage in cardiovascular and anti-diabetic streams, but such initiative appeared category extension, with the intention to diversify risk and expand the company to achieve greater economies of scale. The first year sales revenue for Starpram appeared too bleak to spur further product inaugurations. Consequently, strategic overhaul transpired to establish the brand in the highly fragmented pharmaceutical industry. The firm lacked experience in anti-depressants category, coupled with poor sales, marketing mix and overall marketing strategy. Eventually, the management exercised strategic restructuring to establish brand equity and observed growth. Complexity academic level Study levels/Applicability graduate (MBA), MS, PhD (management sciences). Supplementary materials Teaching Notes are available for educators only. Please contact your library to gain login details or e-mail support@emeraldinsight.com to request teaching notes. Subject code CSS 8: Marketing.
33
Deodhar, A., I. Mcinnes, X. Baraliakos, K. Reich, A. B. Gottlieb, M. Lebwohl, S. Schreiber et al. "FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 722.2–722. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5118.
Texto completoResumen
Background:Pooled safety data has been reported with secukinumab (SEC) in patients (pts) with Psoriatic arthritis (PsA), Ankylosing Spondylitis (AS) and Psoriasis (PsO).1Objectives:To report longer-term safety data of SEC treatment in PsA, AS, PsO pts up to 5 years.Methods:The integrated clinical trial safety dataset included data pooled from 28 randomised controlled clinical trials of SEC 300 or 150 or 75 mg in PsO (11 Phase 3 and 8 Phase 4 trials), PsA (5 Phase 3 trials), and AS (4 Phase 3 trials), along with post-marketing safety surveillance data with a cut-off date of 25 December 2018. Adverse events (AEs) were reported as exposure-adjusted incident rates (EAIRs) per 100 pt-years. Analyses included all pts who received ≥1 dose of SEC.Results:A total of 12637 pts (8819, 2678 and 1140 pts with PsO, PsA and AS, with an exposure of 15063.1, 5984.6 and 3527.2 pt-years, respectively) were included. The most frequent AE was upper respiratory tract infection and EAIR per 100 pt-years for IBD, malignancies and MACE remained low. The EAIR per 100 pt-years for adverse events (AEs) of special interest are reported in Table 1. The cumulative post-marketing exposure to SEC was estimated to be ~285,811 pt-years across the approved indications. Safety data from post-marketing surveillance are reported in Table 2.Table 1.Selected AEs of interest with SEC across pooled clinical trialsVariablePsOPsAASSECN=8819SECN=2678SECN=1140Exposure (Days), Mean (SD)623.9 (567.7)816.2 (580.7)1130.1 (583.0)Death, n (%)15 (0.2)13 (0.5)10 (0.9)Selected AE’s of interest, EAIR (95% CI)Serious infections11.4 (1.2, 1.6)1.8 (1.5, 2.2)1.2 (0.9, 1.6)Candidainfections22.9 (2.7, 3.2)1.5 (1.2, 1.9)0.7 (0.5, 1.1)IBD3Crohn’s disease3Ulcerative colitis30.01 (0.0, 0.05)0.1 (0.05, 0.2)0.1 (0.08, 0.2)0.03 (0.0, 0.1)0.1 (0.04, 0.2)0.1 (0.04, 0.2)0.03 (0.0, 0.2)0.4 (0.24, 0.7)0.2 (0.1, 0.5)MACE40.4 (0.31, 0.5)0.4 (0.3, 0.6)0.7 (0.4, 1.0)Uveitis30.01 (0.0, 0.05)0.1 (0.04, 0.2)1.2 (0.9, 1.7)Malignancy50.9 (0.7, 1.0)1.0 (0.77, 1.3)0.5 (0.3, 0.8)1Rates for system organ class;2Rates for high level term;3Rates for preferred term (PT; IBD for unspecified IBD);4Rates for Novartis MedDRA Query term;5Rates for standardized MedDRA query term – ‘malignancies and unspecified tumour’; EAIR, exposure adjusted incidence rate per 100 pt-years; N, number of pts in the analysisTable 2.Summary of SEC post-marketing safetyExposure (PTY)PSUR126Dec14 -25Jun15PSUR226 Jun - 25Dec15PSUR326Dec15 -25Jun16PSUR426Jun -25Dec16PSUR526Dec16 -25Dec17PSUR626Dec17 -25Dec18Cumulative18387450168712854993744137325285811 n (Reporting rate PTY)Serious infections89 (4.8)149 (2.0)232 (1.4)475 (1.7)649 (0.7)1841 (1.3)3980 (1.4)Malignancy2 (0.1)15 (0.2)21 (0.1)50 (0.2)225 (0.2)422 (0.3)788 (0.3)Total IBD4 (0.2)12 (0.2)37(0.2)46 (0.2)185 (0.2)340 (0.3)693 (0.2)MACE6 (0.3)15 (0.2)16 (0.1)39 (0.1)151 (0.2)238 (0.2)504 (0.2)PSUR, periodic safety update report; PTY, pt-treatment yearsConclusion:In this long-term analysis across clinical trials and post-marketing surveillance, of pts with PsO, PsA and AS, SEC was well tolerated, with a safety profile consistent with previous reports.1Reference:[1]Deodhar et al. Arthritis Research & Therapy (2019) 21:111.Disclosure of Interests:Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Kristian Reich Grant/research support from: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Consultant of: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Speakers bureau: Affibody; Almirall; Amgen; Biogen; Boehringer Ingelheim; Celgene; Centocor; Covagen; Eli Lilly; Forward Pharma; Fresenius Medical Care; GlaxoSmithKline; Janssen; Kyowa Kirin; LEO Pharma; Medac; Merck; Novartis; Miltenyi Biotec; Ocean Pharma; Pfizer; Regeneron; Samsung Bioepis; Sanofi Genzyme; Takeda; UCB; Valeant and Xenoport., Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Mark Lebwohl Grant/research support from: AbbVie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, LLC, Kadmon Corp., LLC, Leo Pharmaceutucals, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc., and ViDac, Consultant of: Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica, Stefan Schreiber Consultant of: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist and Falk, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Kwaku Marfo Shareholder of: Novartis, Employee of: Novartis, Hanno Richards Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Abhijit Shete Shareholder of: Novartis, Employee of: Novartis, Jorge Safi Shareholder of: Novartis, Employee of: Novartis, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau
34
Bradner, Alexandra. "RETHINKING EPISTEMIC INCENTIVES: HOW PATIENT-CENTERED, OPEN SOURCE DRUG DISCOVERY GENERATES MORE VALUABLE KNOWLEDGE SOONER". Episteme 10, n.º 4 (13 de noviembre de 2013): 417–39. http://dx.doi.org/10.1017/epi.2013.33.
Texto completoResumen
AbstractDrug discovery traditionally has occurred behind closed doors in for-profit corporations hoping to develop best-selling medicines that recoup initial research investment, sustain marketing infrastructures, and pass on healthy returns to shareholders. Only corporate Pharma has the man- and purchasing-power to synthesize the thousands of molecules needed to find a new drug and to conduct the clinical trials that will make the drug legal. Against this view, individual physician-scientists have suggested that the promise of applied genomics work calls for a new form of social organization – the open source sharing of molecular probes – in order to speed the generation and understanding of new therapeutics. Recent successes in open source drug discovery show it is possible to produce valuable, empirically adequate, and sustainable collective beliefs without secrecy, proprietary attitudes, initial cooperation from Pharma, or outsized monetary incentives. After reviewing and differentiating these successes, I diagnose the source of this healthy new epistemic strategy.
35
Bhavnani, Sujata M., Jeffrey P. Hammel, Elizabeth A. Lakota, Brian D. VanScoy, Yu Nagira, Christopher M. Rubino, Nobuo Sato, Tomokazu Koresawa, Kenichiro Kondo y Paul G. Ambrose. "1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection". Open Forum Infectious Diseases 5, suppl_1 (noviembre de 2018): S427—S428. http://dx.doi.org/10.1093/ofid/ofy210.1223.
Texto completoResumen
Abstract Background ME1100 (arbekacin inhalational solution) is an inhaled aminoglycoside being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). PK-PD target attainment analyses were undertaken to evaluate ME1100 regimens for patients with HABP/VABP arising from Klebsiella pneumoniae (KP), Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA), including those with renal impairment. Methods Data used included a population pharmacokinetic (PPK) model developed using Phase 1 and post-marketing PK data, nonclinical PK-PD targets from one compartment in vitro and/or in vivo infection models, and MIC data. Using parameter estimates from the PPK model (four-compartment model with first-order elimination), total-drug epithelial lining fluid concentration-time profiles were generated for simulated patients with varying creatinine clearance (CLcr; mL/minute/1.73 m2) and by CLcr group. Twice daily (BID) ME1100 regimens ranging from 300 to 900 mg were assessed in simulated patients with CLcr >80 to ≤120 mL/minute/1.73 m2. Percent probabilities of PK-PD target attainment by MIC were determined based on total-drug ELF AUC:MIC ratio targets associated with 1- and 2-log10 CFU reductions from baseline for KP, PA and SA using Day 1 AUC. Regimens in simulated patients with renal impairment that best matched the BID regimen in the normal CLcr group with high percent probabilities of PK-PD target attainment and a low percent probability of Cmin > 2 mg/L were identified. Results ME1100 600 mg BID in simulated patients with CLcr >80 to ≤120 mL/minute/1.73 m2, with 600 mg once daily, 450 mg BID and 600 mg BID in simulated patients with CLcr of 0 to ≤30, >30 to ≤50 and >50 to ≤80 mL/minute/1.73 m2, respectively, achieved high percent probabilities of PK-PD target attainment based on PK-PD targets for a 1-log10 CFU reduction from baseline at relevant MIC values for KP, PA and SA, and relatively lower Cmin values. In simulated patients with varying CLcr who received these regimens, high percent probabilities of PK-PD target attainment were achieved for KP, PA and SA at the upper margins of the MIC distributions (Figures 1–3). Conclusion The data provide support for ME1100 dose selection for patients with HABP/VAPB. Disclosures S. M. Bhavnani, Meiji Seika Pharma Co. Ltd.: Research Contractor, Research support. J. P. Hammel, Meiji Seika Pharma Co. Ltd.: Research Contractor, Research support. E. A. Lakota, Meiji Seika Pharma Co. Ltd.: Research Contractor, Research support. B. D. VanScoy, Meiji Seika Pharma Co. Ltd.: Research Contractor, Research support. Y. Nagira, Meiji Seika Pharma Co. Ltd.: Employee, Salary. C. M. Rubino, Meiji Seika Pharma Co. Ltd.: Research Contractor, Research support. N. Sato, Meiji Seika Pharma Co. Ltd.: Employee, Salary. T. Koresawa, Meiji Seika Pharma Co. Ltd.: Employee, Salary. K. Kondo, Meiji Seika Pharma Co. Ltd.: Employee, Salary. P. G. Ambrose, Meiji Seika Pharma Co. Ltd.: Research Contractor, Research support.
36
Czarka, Marc y Rick Ng. "Drug truths: Dispelling the myths of pharma R&D". Journal of Medical Marketing 9, n.º 3 (julio de 2009): 275–76. http://dx.doi.org/10.1057/jmm.2009.22.
Texto completo
37
Mukherjee, Rajib. "Application & scope of IT in the Indian pharma sector". Journal of Medical Marketing 6, n.º 2 (marzo de 2006): 146–50. http://dx.doi.org/10.1057/palgrave.jmm.5050022.
Texto completo
38
Reddy, D. Samba. "New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States". International Journal of Pharmaceutical Sciences and Nanotechnology 6, n.º 2 (31 de agosto de 2013): 2009–13. http://dx.doi.org/10.37285/ijpsn.2013.6.2.1.
Texto completoResumen
Thirty-nine (39) new drugs have been approved by the U.S. FDA in 2012, a record highest number of approvals since 1996. The record is a sign that pharma companies are poised to tap recent advances from genomics and proteomics. This list includes novel new drugs, known as new molecular entities (NMEs), biologics and new products. Many life-saving drugs are approved for marketing. The list includes a total of 10 drugs for cancer treatment, and nearly a quarter of those approved in 2012 had orphan drug status. Among the breakthrough drugs approved in 2012 were ivacaftor (cystic fibrosis), vasmodegib (skin cancer), HPC-C (human cord blood product), ruxolitinib (myelofibrosis) and a new combination drug to treat HIV. In addition, several unique products were approved for the treatment of macular degeneration, chronic weight management, overactive bladder, actinic keratosis, erectile dysfunction, glaucoma, respiratory distress syndrome, and COPD. The approval of 39 drugs in 2012 underscores a robust success rate and confirms that innovation is once again beginning to pay off. In the existing climate of reduced revenues in the face of generic competitions, the future and survival of big companies rests heavily on their unique niche products. It is apparent that big Pharma and a growing number of emerging Biotechs alike have focused their attention on developing new NMEs for rare diseases. In 2012, the length of the FDA’s review is shorter than agencies in other countries. Innovative models adopted for R&D strategies, communications, and new regulatory changes appear to shorten development timelines. Despite record drug approvals, there is bleak scope for blockbusters because most of these drugs have a limited market. The pipeline for blockbusters appears very low. However, there is unmet medical need for new drugs in autism, Alzheimer’s disease and epilepsy. Overall, the new drug approval list unveils unique and reemerging trends indicating that the pharma companies are poised for big growth from new brands approved for marketing for narrow-spectrum indications.
39
Sattar, Muhammad Muzamil, Asad Ali Qazi, Farhan Shahzad y Abdul Rehman Shaikh. "Flori Pharma: maintaining ethics in an unethical sales environment". Emerald Emerging Markets Case Studies 10, n.º 1 (13 de marzo de 2020): 1–21. http://dx.doi.org/10.1108/eemcs-07-2019-0187.
Texto completoResumen
Learning outcomes The learning outcomes are as follows: what tasks are to be done by medical representatives in pharmaceutical industry? This study also highlights various competencies required to do effective selling in this industry; analyzes and discusses different unethical practices going on in the market; explains why ethical norms are necessary in sales context when sales targets are already achievable with unethical means; and develops and comments on strategies Flori Pharmaceutical can make to overcome on these unethical issues. What should be the response of Dahar to the email of Naveed khan? What course of action should be taken by Dahar in the deceitful reporting case of Mohsin Ali? Case overview/synopsis Flori is considered a leading and growing multinational organization in the highly competitive environment of Pakistan pharmaceutical industry with over 40 years of experience. The company aims to command a leading position in developing new health-care products as it offers a wide range of diabetic, cardiovascular, respiratory and vitamin products based on quality as a result of high research and examination. Recently, an email to Bilal Dahar on March 2017 from Flori’s star sales person Naveed Khan has forced management to take some strong decisions regarding ethical norms and values to be adopted by medical representatives of Flori pharmaceuticals. The email highlighted the issues related to sales pressure which are leading toward unethical sales practices. Dahar just not have to maintain Flori’s ethical code of conduct but he and his team also has to work hard to achieve more than 26% growth rate in sales revenue as compared to last year. Dahar knew that the highly competitive environment of pharmaceutical industry has led most of the stake holders to indulge in unethical behavior to achieve their individual targets. He knew that this is dangerous in long term for the multinational organizations such as Flori pharmaceuticals as if the similar behavior continues, the sales culture and values of the organization would be on stake. He also has to decide what decision to be taken against deceitful reporting issue of one of the top-performer territory managers, who was key person in helping Flori to close the sales year 2016 with the revenue of Rs. 6.4bn, a 26% growth over the last year. The case is rich enough to provide a platform regarding management of several ethical challenges in pharmaceutical selling and developing strategies based on them. Complexity academic level BBA, MBA final year. Supplementary materials Teaching Notes are available for educators only. Subject code CSS 8: Marketing.
40
Stasevych, M. V. y V. I. Zvarych. "Marketing analysis of the market segment of drugs – derivatives of 9,10-anthraquinone in Ukraine". Chemistry, Technology and Application of Substances 4, n.º 1 (1 de junio de 2021): 116–25. http://dx.doi.org/10.23939/ctas2021.01.116.
Texto completoResumen
A marketing analysis of the pharmaceutical market for drugs - derivatives of 9,10-anthraquinone was carried out. It is shown that in the Ukrainian market, the vast majority of the assortment of these drugs is formed by foreign-made drugs, the leaders of which are the manufacturing countries Austria, Italy, Germany and India. It has been determi ned that the majority of anthraquinone drugs are represented by agents for the treatment of diseases of various types of cancer and strengthening of the intestinal reticulum. It has been established that “Sinbias Pharma” LLC is engaged in the production of four anticancer substances in Ukraine. For preparations based on anthraquinone-containing medicinal herbal raw materials, domestic manufacturers are PJSC “Liktravy” and PJSC Pharmaceutical Factory “Viola”, and the producers of senna glycosides are JSC “Lubnypharm”, “Ternopharm” LLC and Pharmaceutical company “Zdorovye”. Injection solutions, lyophilisates, tablets and hard capsules are the main dosage forms of drugs – derivatives of 9,10-anthraquinone.
41
Singh, Sunil y Gavin Outteridge. "India’s proposed universal health coverage scheme – Implications for the global pharma industry". Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing 13, n.º 3 (25 de junio de 2013): 181–93. http://dx.doi.org/10.1177/1745790413493284.
Texto completo
42
Moss, Giles y Isabelle Schuiling. "A brand logic for pharma?: A possible strategy based on FMCG experience". Journal of Medical Marketing 4, n.º 1 (1 de enero de 2004): 55–62. http://dx.doi.org/10.1057/palgrave.jmm.5040143.
Texto completo
43
R.M., Harindranath, Bharadhwaj Sivakumaran y Jayanth Jacob. "The moderating role of sales experience in adaptive selling, customer orientation and job satisfaction in a unionized setting". Journal of Business & Industrial Marketing 34, n.º 8 (7 de octubre de 2019): 1724–35. http://dx.doi.org/10.1108/jbim-08-2018-0233.
Texto completoResumen
Purpose The principal purpose of this study is to examine the moderating influence of selling experience on the following two relationships – adaptive selling and job satisfaction and customer orientation and job satisfaction – using unionized salespeople as respondents. It also tests for the mediating role of adaptive selling in the customer orientation–job satisfaction relationship. Design/methodology/approach This paper uses data from a survey conducted on 208 pharmaceutical unionized salespeople from 46 pharmaceutical firms in India. The model was tested using structural equation modeling. Moderation hypotheses were estimated using process macro and the Johnson–Neyman technique. Findings The data fitted the model well. This research found that customer orientation drove adaptive selling behavior and job satisfaction, and that adaptive selling influenced job satisfaction (all positively); it was found that adaptive selling partially mediated the relationship between customer orientation and job satisfaction. Results revealed that job experience negatively moderated the adaptive selling behavior–job satisfaction and customer orientation–job satisfaction relationships. Practical implications The results show that pharma firms may hire young recruits and, importantly, measure their customer orientation and adaptive selling levels. For the purposes of training to enhance customer orientation and adaptive selling, pharma firms may send only their less experienced salespersons. Originality/value To the authors’ knowledge, this study could be the first to examine the interaction of job experience and customer-directed selling behaviors such as adaptive selling and customer orientation on job satisfaction. Moreover, this is possibly the only study in this domain that uses unionized salespeople in an emerging market (India).
44
Kernder, A., H. Morf, P. Klemm, D. Vossen, M. Meyer, I. Haase, J. Mucke et al. "POS1458-HPR DIGITAL RHEUMATOLOGY IN THE ERA OF COVID-19: RESULTS OF A NATIONAL PATIENT AND PHYSICIAN SURVEY". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de mayo de 2021): 1013–14. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1328.
Texto completoResumen
Background:Digital health applications (DHAs) are gaining influence and promise great potential for the monitoring and management of rheumatic and musculoskeletal diseases (RMDs).Objectives:To analyse the impact of the COVID-19 pandemic on RMD patients’ and rheumatologists’ usage, preferences, and perception of digital health applications (DHAs) in Germany.Methods:A web-based national survey was developed by the Working Group Young Rheumatology of the German Society for Rheumatology and the German League against Rheumatism. The prospective survey was distributed via social media, QR-code, and email. Descriptive statistics were calculated, and regression analyses were performed to show correlations.Results:We analysed the responses of 299 patients and 129 rheumatologists. Most patients (74%) and rheumatologists (76%) believed that DHAs are useful in the management of RMDs and felt confident in their own usage thereof (90%; 86%). 38% of patients and 71% of rheumatologists reported that their attitude had changed positively towards DHAs and that their usage had increased due to COVID-19 (29%; 48%).Usage and recommendation of DHAs for both groups are shown in Figure 1:Figure 1.Usage or recommendation of digital health applications. Patients and rheumatologists were asked to indicate the specific digital health applications (DHAs) they used or were recommended.The majority in both groups agreed on implementing virtual visits for follow-up appointments in stable disease conditions. The most reported advantages of DHAs were usage independent of time and place (76.6%; 77.5%). The main barriers were a lack of information on suitable, available DHAs (58.5%; 41.9%), poor usability (42.1% of patients) and a lack of evidence supporting the effectiveness of DHAs (23.2% of rheumatologists) (Table 1).Table 1.Advantages and Barriers of DHA, n (%).AdvantagesBarriersPatientsRheumatologistsPatientsRheumatologistsLocation-Independence229 (76.6)100 (77.5)Too little information175 (58.5)54 (41.9)Time-independence223 (74.6)94 (72.9)Too little evidence of benefits36 (12.0)30 (23.3)Detailed documentation97 (32.4)47 (36.4)Poor quality of current apps47 (15.7)29 (22.5)Cost saving95 (31.8)37 (28.7)Concernsabout data protection52 (17.4)25 (19.4)More information88 (29.4)38 (29.5)Lack of usability126 (42.1)17 (13.2)Independenceof doctors+36 (12.0)-Lack of accessibility4 (1.3)-More flexibility107 (36.8)77 (59.7)High costs4 (1.3)23 (17.8)Preparationfor discussion+46 (15.4)-No suitable equipment17 (5.7)11 (8.5)No advantages at all18 (6.0)1 (0.8)Lack of user competenceNo Need9 (3.0)39 (13.0)-12 (9.3)Patients and rheumatologists were asked about the advantages and barriers of DHAs. Multiple answers were allowed. Patients had two additional potential advantages and potential barriers to choose from*.Only a minority (<10% in both groups) believed that digitalisation has a negative impact on the patient-doctor relationship.Conclusion:The COVID-19 pandemic instigated an increase in patients’ and rheumatologists’ acceptance and usage of DHAs, possibly introducing a permanent paradigm shift in the management of RMDs.Acknowledgements:The authors thank the following persons and societies for their great effort, distributing the online survey: P.Aries, A.Hueber, E.Feist, C.Fiehn, P.Korsten, I.Kötter, F.Mühlensiepen, A.Pfeil, M.Rudwaleit, M.Welcker, S.Zinke, Deutsche Vereinigung Morbus Bechterew e.V., Deutsche Rheuma-Liga Bundesverband e. V., Sklerodermie Selbsthilfe e.V.Disclosure of Interests:Anna Kernder: None declared, Harriet Morf: None declared, Philipp Klemm: None declared, Diana Vossen Speakers bureau: Novartis, Abbvie, Amgen, Consultant of: Abbvie Deutschland GmbH & Co. KG, Bristol-Myer Squibb, Celgene GmbH, Gilead Sciences Inc., Lilly Deutschland GmbH, Medac GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH, UCB Pharma GmbH, Grant/research support from: Pfizer, Abbvie, Marco Meyer Consultant of: Medac, Isabell Haase Speakers bureau: Medac, Consultant of: Medac, Grant/research support from: UCB, Abbvie, BMS, Johanna Mucke Speakers bureau: AbbVie Deutschland GmbH & Co. KG, Amgen, Bristol-Myers Squibb, Chugai Pharma Germany GmbH, Celgene GmbH, Gilead Sciences Inc., GlaxoSmithKline, Janssen-Cilag GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH and UCB Pharma GmbH., Consultant of: AbbVie Deutschland GmbH & Co. KG, Amgen, Bristol-Myers Squibb, Chugai Pharma Germany GmbH, Celgene GmbH, Gilead Sciences Inc., GlaxoSmithKline, Janssen-Cilag GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH and UCB Pharma GmbH., Arnd Kleyer Shareholder of: yes, Speakers bureau: Lilly, Novartis, Consultant of: Abbvie, Lilly, Novartis BMS, Gilead,Janssen, Grant/research support from: Lilly, Novartis, Gilead,, Philipp Sewerin Consultant of: AbbVie, Amgen, Axiom Health, Biogen, Bristol-Myers Squibb, Celgene, Chugai Pharma Marketing Ltd./Chugai Europe, Deutscher Psoriasis-Bund, Fresenius Kabi, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly, Medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein-Ruhr, Sanofi-Genzyme, Swedish Orphan Biovitrum, and UCB, Grant/research support from: AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Bundesministerium fuer Bildung und Forschung (BMBF), Deutsche Forschungsgesellschaft (DFG), Deutscher Psoriasis-Bund, Fresenius Kabi, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Lilly, Novartis Pharma, Pfizer, Rheumazentrum Rhein-Ruhr, Roche Pharma, Sanofi-Genzyme, and UCB, Gerlinde Bendzuck: None declared, Sabine Eis: None declared, Johannes Knitza Consultant of: Abbvie, Novartis, Lilly, Medac, BMS, Sanofi, Amgen, Gilead, UCB, ABATON, GSK, Grant/research support from: Novartis, UCB, Thermofisher, Sanofi, Martin Krusche Speakers bureau: Lilly, Medac, Novartis, Roche/Chugai, Consultant of: Abbvie, Lilly, Gilead, Medac, Novartis, Sobi, BMS, Amgen, GSK, Grant/research support from: Sanofi
45
G. Goncharuk, Anatoliy y Maryna Getman. "Benchmarking to improve a strategy and marketing in pharmaceuticals". Benchmarking: An International Journal 21, n.º 3 (29 de abril de 2014): 364–85. http://dx.doi.org/10.1108/bij-06-2012-0041.
Texto completoResumen
Purpose – The paper is devoted to benchmark strategic ideas, organizational culture, marketing business processes and key marketing performance measures of the pharmaceutical companies that operate on Ukrainian pharma market in order to determine the best practices and possibilities of their use for the purpose of improving performance outcomes of companies participating in the research. Design/methodology/approach – The AllFusion Process Modeler 7 software was used for processes modeling. The Balanced Scorecard Designer software was used to create balanced scorecard. The classifier of processes at pharmaceutical companies designed by American Productivity and Quality Center (APQC) was used when determining marketing processes and building process maps. A marketing analysis (value market share, share of voice, secondary sales dynamics and companies' market share growth dynamics) was carried out in order to estimate the efficiency of marketing process. Findings – The study showed that three pharmaceutical companies have different strategic aims, mission and vision. For the global companies, a strategic aim is “Market takeover”, while the local company tries just to retain its position on the market due to some historically prevailing conditions. The study showed that local company's management does not consider marketing as a driving force of the development and sales growth; that is why company lacks marketing culture and marketing department as such is substituted with sales and distribution department. The authors find the needs of structural changes in order to develop, yield profit and avoid acquisition by local pharmaceutical company using the better practice of the global companies. Research limitations/implications – The research is limited by a little number of companies (three) and one country market (Ukraine). Practical implications – The study includes practical recommendations focused on the improvement of financial indicators and profitability of the local pharmaceutical company with a use of benchmarking tools. They can be useful for the other local companies that try to compete with global pharmaceutical companies on the local markets. Originality/value – This paper adopts the various benchmarking tools to improve a strategy and marketing processes for pharmaceutical companies.
46
Banerjee, Saikat y Sampada Kumar Dash. "Factors Influencing Adoption of E-detailing as a Communication Tool". International Journal of E-Health and Medical Communications 5, n.º 3 (julio de 2014): 29–39. http://dx.doi.org/10.4018/ijehmc.2014070103.
Texto completoResumen
In India, the concept of Electronic detailing (E-detailing) as a marketing communication tool is getting momentum in recent times. However, to ensure wide acceptance and long term sustainability of this tool, pharma companies should well aware about the factors that influence adoption of E-detailing by Indian Physicians. Still, to the best of our knowledge, there is limited academic research in this area. In this backdrop, the objective of this study is to unearth factors that influence adoption of E-detailing by Physicians of India. Research outcome may help pharma companies to draw a strategic communication roadmap for effective use of E-detailing for product message communication to the Physicians. The study is based on primary data collected from the Delhi/ National Capital Region (NCR) area from India. To analyze the data, an attempt is made to identify latent factors that influencing various measurable characteristics. Approach of Gonzalez et al. (2002) is used in factor analyzing the responses to identify prominent influencing factors behind the adoption of E-detailing by Physicians. As viewed by the physicians, communication credibility and convenient communication are two most important impetuses for adoption of E-detailing. Other important motivating factors are managing Professional Service Representatives (PSRs), information accessibility and empowered decision making.
47
Burrows, Christopher. "Should the pharma/healthcare sector look further afield for world class leadership talent?" Journal of Medical Marketing 7, n.º 1 (enero de 2007): 93–95. http://dx.doi.org/10.1057/palgrave.jmm.5050058.
Texto completo
48
Ramchandren, Radhakrishnan, Charles A. Schiffer, Radhakrishnan Ramchandren y Charles A. Schiffer. "ReCAP: Pattern of Duplicate Presentations at National Hematology-Oncology Meetings: Influence of the Pharmaceutical Industry". Journal of Oncology Practice 12, n.º 3 (marzo de 2016): 252–53. http://dx.doi.org/10.1200/jop.2015.004523.
Texto completoResumen
CONTEXT AND QUESTION ASKED: The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) annual meetings are two of the largest conferences in the fields of hematology and oncology. These meetings are attended by physicians, researchers, pharmaceutical industry colleagues, and representatives from the media and business sectors. The intention of both societies, as stated in their submission guidelines, is to accept abstracts that have not previously been presented. These policies are presumably in place to minimize redundancy and, due to time and space constraints, allow the largest number of researchers to present their findings. Hence, we asked, are there duplicative presentations at these two large meetings, and if so, how often do they occur? METHODS—WHAT WE DID: To date, however, the success of the societies in eliminating duplication has not been carefully analyzed. In addition, the motivations behind re-presentation have not been evaluated objectively. Therefore, we conducted a review of 327 malignant hematology (non-transplantation) abstracts presented at ASCO 2010 and compared them with prior and subsequent ASCO and ASH meetings to evaluate the incidence of duplicate presentations and their relationship to funding sources over a 2 year time frame. RESULTS—WHAT WE FOUND: Our analysis indicated that 31% of accepted abstracts were duplicated during the 2-year time frame, with those indicating pharmaceutical support three times more likely to be duplicated ( Figure 1 ). IMPLICATIONS FOR PRACTICE & LIMITATIONS OF DATA: These findings suggest that a substantial number of duplicative abstracts are re-presented, with a disproportionate number having pharma sponsorship. The motivations for duplication are varied but may include an influence of pharma marketing strategies. Although these results are limited by our search strategy and to this 2-year time frame, the results were similar when we analyzed ASH and ASCO 2014 leukemia abstracts. These findings demonstrate the need for a more effective abstract selection system and that further study of the role of marketing in large meetings such as ASCO and ASH would be appropriate. [Figure: see text]
49
Puetz, John y Florian M. Wurm. "Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing". Processes 7, n.º 8 (24 de julio de 2019): 476. http://dx.doi.org/10.3390/pr7080476.
Texto completoResumen
Recombinant proteins have been produced for over 30 years. Applications range from enzymes used in laundry detergents to antigen-detecting antibodies in cancer therapy. Despite similarities in manufacturing, drastic differences in retail pricing between recombinant proteins used for industrial (non-medical) versus pharmaceutical purposes exist. Industrial proteins often have a retail price in the tens of dollars per kilogram while recombinant proteins for medical use may cost billions of dollars per kilogram. This manuscript will briefly review manufacturing techniques and contrast the differences between industrial versus pharmaceutical production. Maximizing manufacturing technologies to reduce cost-of-goods (CoG) is desirable. However, the major reason for the very high pricing of pharma protein products does not reflect CoG, but the financial obligations of clinical trials, research and development, patent constraints, marketing, and return on investment.
50
McNamara, Linda. "Market Dynamics — In search of double-digit revenue growth: Can big pharma hit its numbers?" Journal of Medical Marketing 4, n.º 1 (1 de enero de 2004): 18–26. http://dx.doi.org/10.1057/palgrave.jmm.5040139.
Texto completo